MeiraGTx has secured a royalty-backed financing deal with Oberland Capital for up to $375 million. The agreement provides an immediate $100 million, with future tranches tied to the success of its lead gene therapy programs, including treatments for retinitis pigmentosa and dry mouth caused by radiation therapy. In exchange, Oberland receives a capped 1.95% royalty on global net sales of these products once approved.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding MeiraGTx Holdings plc (MGTX)?

Major stakeholders currently include Sanofi ($105.6M), Perceptive Advisors LLC ($89.3M), Rubric Capital Management LP ($60.6M). Based on the latest 13F filings, there are a total of 133 tracked investment funds and institutions maintaining positions in MGTX.

What is the overall institutional sentiment toward MGTX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $65.0M, driven by 67 managers accumulating shares while 56 reduced their exposure.

Which institutions have been selling or reducing their MGTX positions?

In the latest period, 40 funds trimmed their holdings, and 16 managers completely exited their positions. The aggregate reported sell value was $97.1M.

Are there any notable investors adding MGTX to their portfolios?

Yes, buying activity remains notable. 18 institutions opened new positions in {ticker}, and 49 existing holders added to their shares. The total reported buy value for the quarter amounted to $191.7M.